Medigene AG: bluebird bio and Medigene establish strategic T cell receptor (TCR) alliance in cancer immunotherapy
T cell receptor (TCR) therapeutic candidates against four targets to be generated using Medigene's proprietary TCR techn…
T cell receptor (TCR) therapeutic candidates against four targets to be generated using Medigene's proprietary TCR techn…
Medigene AG (MDG1, Frankfurt, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T…
Medigene AG (MDG1, Frankfurt, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T…
Patent covers a rapid and efficient method for identifying tumor-specific antigens Expected to facilitate the use of neo…
Medigene AG (MDG1, Frankfurt, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T…
Medigene AG (MDG1, Frankfurt, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T…
Medigene AG (MDG1, Frankfurt, Prime Standard), a clinical stage immune-oncology company focusing on the development of T…
Die Medigene AG (MDG1, Frankfurt, Prime Standard), ein Immunonkologie-Unternehmen mit klinischen Entwicklungsprojekten…
Medigene AG (MDG1, Frankfurt, Prime Standard), a clinical stage immune-oncology company focusing on the development of T…
Medigene AG (MDG1, Frankfurt, Prime Standard), a clinical stage immune-oncology company, announced the treatment start o…